Adaptive Biotechnologies
Adaptive is an immune medicine company focused on translating the genetics of the adaptive immune system into clinical products to detect and treat disease.
Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries
04/29/2026
What happens when models learn directly from large-scale T cell activation data?
In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. https://adaptivebio.tech/6xq
04/13/2026
How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at ) explores a data-driven approach using large-scale T-cell activation data. Read more:
Predicting T Cell Recognition: New Insights from Large-Scale Activation Data A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell activation data can improve prediction of T cell receptor recognition, a longstanding challenge in computational immunology with implications for cancer and autoimmune disease. Predicting how T-cell re...
This , hear from Allison Jacob, VP Medical Affairs, how MRD testing is informing care decisions across the myeloma journey. Adaptive is working to help bring better outcomes to people living with lymphoid malignancies.
03/08/2026
This , Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.”
03/03/2026
March is Myeloma Action Month. 🩸
Taking action starts with awareness. Understanding what remains can change what comes next.
02/25/2026
This Black History Month, we’re proud to recognize Nyabuom Chuol, a Senior Clinical Services Specialist and leader of our Black Adapter Network ERG.
Through her dedication, Nyabuom has helped foster meaningful connections between our workplace and the broader community—creating spaces where Black culture is recognized, celebrated, and uplifted.
Thank you, Nyabuom, for shaping a culture of belonging that strengthens our company every day.
02/04/2026
We’re honored to be named a recipient of the Equity 100 Award from the Human Rights Campaign Foundation’s Corporate Equality Index — a national benchmark that measures corporate commitment to equity and inclusion. This recognition reflects the meaningful steps our team has taken to foster a workplace where everyone can bring their whole self to work and thrive.
We’re grateful to every team member who has helped shape a culture that celebrates diversity, advances equity, and invests in inclusion.
01/07/2026
We’re excited to kick off the year at . CEO Chad Robins will present on Monday, January 12 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast of the event will be available in the investors section of our website. https://adaptivebio.tech/qf0
As we close out the year, we’re grateful for the curiosity, collaboration, and innovation that drive our work—and the colleagues and partners who make it possible.
Reaching 100,000 unique patients tested with clonoSEQ® is more than a milestone — it represents thousands of individual journeys through diagnosis, monitoring, and treatment.
We’re honored to play a role in helping patients and their care teams make more informed decisions with clarity and confidence.
Learn more: https://adaptivebio.tech/tyz
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
1165 Eastlake Avenue E
Seattle, WA
98109
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |